CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
AACC 2013
September 2013—Abbott has received FDA approval to expand the use of its RealTime HIV-1 assay to run on the company’s mPlus system.
In April, Abbott introduced mPlus capability for its RealTime m2000 system to enhance the system’s flexibility and make molecular testing easier and more efficient for laboratories. The new mPlus makes it possible for laboratories of any size to perform molecular diagnostic tests for infectious disease detection and therapy monitoring.
mPlus capability is now available for Abbott’s RealTime HIV-1 and CT/NG assays within the United States and for the RealTime HIV, HCV, HBV, CT/NG, and CT assays outside the United States.
Abbott’s mPlus will allow laboratories to process samples when they are ready rather than holding them for larger batch runs, providing faster results to physicians and patients. mPlus capability will also optimize reagent use, reduce laboratory cost of operations, and offer a new automatic inventory feature to improve system ease of use.